Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Agios Pharmaceuticals stock on January 29th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of ICF International NASDAQ: ICFI on 2/3/2025.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 1/31/2025.
• Purchased $50,001 - $100,000 in shares of Hawaiian Electric Industries NYSE: HE on 1/31/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 1/30/2025.
• Purchased $1,001 - $15,000 in shares of SpringWorks Therapeutics NASDAQ: SWTX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Paragon 28 NYSE: FNA on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of U.S. Physical Therapy NYSE: USPH on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 1/29/2025.
• Purchased $1,001 - $15,000 in shares of Lantheus NASDAQ: LNTH on 1/28/2025.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO traded down $0.08 during mid-day trading on Friday, hitting $33.22. 786,683 shares of the company's stock traded hands, compared to its average volume of 609,544. The firm's 50 day simple moving average is $35.19 and its 200 day simple moving average is $43.36. Agios Pharmaceuticals, Inc. has a 1 year low of $24.88 and a 1 year high of $62.58. The company has a market cap of $1.89 billion, a PE ratio of 2.92 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.93% and a net margin of 2,051.38%. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company's stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on AGIO. Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $56.33.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after acquiring an additional 216,484 shares during the last quarter. Vestal Point Capital LP acquired a new position in Agios Pharmaceuticals during the third quarter valued at approximately $33,767,000. BNP Paribas Financial Markets lifted its position in Agios Pharmaceuticals by 15.1% during the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock valued at $531,000 after buying an additional 1,570 shares in the last quarter. SG Americas Securities LLC acquired a new position in Agios Pharmaceuticals during the third quarter valued at approximately $705,000. Finally, FMR LLC lifted its position in Agios Pharmaceuticals by 283.2% during the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after buying an additional 33,546 shares in the last quarter.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.